Ensysce Biosciences Inc.
ENSC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENSC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENSC
Ensysce Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel therapies for chronic pain and infectious disease, with lead candidates PF614, PF614-MPAR, and nafamostat. The company has yet to complete any pivotal clinical trials or obtain regulatory approval and faces significant capital needs to fund ongoing operations.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for Ensysce Biosciences Inc..
Ensysce Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel therapies for chronic pain and infectious disease, with lead candidates PF614, PF614-MPAR, and nafamostat. The company has yet to complete any pivotal clinical trials or obtain regulatory approval and faces significant capital needs to fund ongoing operations.
- Lead product candidates include PF614, PF614-MPAR (for chronic pain) and nafamostat (for infectious disease) [sec_mda · as of 2026-08-13].
- Cash and equivalents were $0.7M as of 2026-06-30, with shareholders' equity of $3.2M and total debt of $0.2M [sec].
- The company has incurred significant operating losses since inception and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-13].
- Ensysce has not completed any pivotal clinical trials, obtained regulatory approvals, manufactured commercial-scale drug, or conducted sales and marketing activities [sec_mda · as of 2026-08-13].
- The company's ability to continue as a going concern is dependent on raising additional capital [sec_mda · as of 2026-08-13].
What works
- The company is advancing a pipeline of product candidates targeting chronic pain and infectious disease, addressing significant unmet medical needs [sec_mda · as of 2026-08-13].
- Ensysce has a structured development plan for its lead candidates, including ongoing preclinical and clinical trials [sec_mda · as of 2026-08-13].
What to weigh
- Ensysce has not completed any pivotal clinical trials or obtained regulatory approval for any product candidate, indicating a high-risk development stage [sec_mda · as of 2026-08-13].
- The company has incurred significant operating losses since inception and expects to continue incurring net losses, with no assurance of future profitability [sec_mda · as of 2026-08-13].
- Cash and equivalents of $0.7M as of 2026-06-30 are limited, and the company's future viability depends on raising additional capital, which may not be available on favorable terms [sec_mda · as of 2026-08-13].
- There is a risk of Nasdaq delisting if the company fails to maintain compliance with applicable listing standards [sec · filed 2026-06-04].
From the filings
Quoted directly from source documents.
Ensysce has not completed any pivotal clinical trials or obtained regulatory approvals.
“any pivotal clinical trials, nor have we obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.”
SEC MD&A · August 13, 2026
The company has incurred significant operating losses since inception.
“We have incurred significant operating losses since inception, and we expect to continue to incur net losses for the foreseeable future.”
SEC MD&A · August 13, 2026
Future viability depends on raising additional capital.
“Our future viability beyond the twelve months is dependent on our ability to raise additional capital to finance our operations.”
SEC MD&A · August 13, 2026
Cash on hand was sufficient only into late second quarter of 2026.
“Our current cash on hand is sufficient to fund operations into the late second quarter of 2026.”
SEC filings · June 4, 2026
Catalyst timeline
- 2026-11-01 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet — Topline results from a pivotal Phase 3 trial will provide key data on efficacy and safety of the lead candidate.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Ensysce has no approved products, no commercial manufacturing, and no sales history, with all candidates in development [sec_mda · as of 2026-08-13].
- Limited cash runway — Cash of $0.7M as of 2026-06-30 is insufficient to fund operations beyond the near term, requiring additional financing [sec].
- Going concern uncertainty — The company's ability to continue as a going concern is dependent on raising capital, with risk of delay or discontinuation of programs [sec_mda · as of 2026-08-13].
- Nasdaq delisting risk — Failure to maintain compliance with Nasdaq listing standards could result in delisting of common stock [sec · filed 2026-06-04].
What to watch
- Phase 3 topline data for PF614 expected on 2026-11-01, which will be a key efficacy and safety readout [catalyst].
- Ability to raise additional capital to extend cash runway beyond current $0.7M as of 2026-06-30 [sec].
- Progress in preclinical and clinical trials for PF614-MPAR and nafamostat [sec_mda · as of 2026-08-13].
- Regulatory interactions and any updates on FDA approval pathways [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Ensysce Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ensysce Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
2.0 months
OCF -$2M
Lead: Phase 3
2 candidates
1 upcoming, next in ~63d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$307K
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 173,332 | $93K |
| adage capital partners gp, l.l.c. | 149,711 | $81K |
| geode capital management, llc | 73,880 | $40K |
| citadel advisors llc | 57,363 | $31K |
| vanguard capital management llc | 25,708 | $14K |
| xtx topco ltd | 24,363 | $13K |
| vanguard fiduciary trust co | 23,854 | $13K |
| jane street group, llc | 13,570 | $7K |
| tru independence asset management 2, llc | 13,000 | $7K |
| ubs group ag | 8,791 | $5K |
Showing top 10 of 14 institutional holders of Ensysce Biosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.6%
- Days to cover
- 0.2
- Shares short
- 52,730
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENSC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ensysce Biosciences Inc.?
Ensysce Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel therapies for chronic pain and infectious disease, with lead candidates PF614, PF614-MPAR, and nafamostat. The company has yet to complete any pivotal clinical trials or obtain regulatory approval and faces significant capital needs to fund ongoing operations.
What is Ensysce Biosciences Inc.'s lead drug candidate?
Ensysce Biosciences Inc.'s most advanced tracked candidate is pf614 (Phase 3) for Postoperative Pain, Acute; Pharmacokinetics.
What is Ensysce Biosciences Inc.'s next catalyst?
Ensysce Biosciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet" — expected November 1, 2026.
Who is the CEO of Ensysce Biosciences Inc.?
Dr. D. Lynn Kirkpatrick Ph.D. is the chief executive officer of Ensysce Biosciences Inc. (ENSC).
Where is Ensysce Biosciences Inc. headquartered?
Ensysce Biosciences Inc. (ENSC) is headquartered in La Jolla, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.